Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK6097608 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Participants receiving GSK6097608 monotherapy (Arm A) | EXPERIMENTAL | Participants will be administered an intravenous (IV) infusion of GSK6097608 every 3 weeks as monotherapy in escalating doses. |
| Participants receiving GSK6097608 plus dostarlimab (Arm B) | EXPERIMENTAL | Participants will be administered IV infusion of GSK6097608 every 3 weeks in escalating doses followed by dostarlimab. |
| Participants receiving dostarlimab monotherapy (Arm D) | EXPERIMENTAL | Participants will be administered an IV infusion of dostarlimab monotherapy (1 cohort will receive dostarlimab every 3 weeks and 1 cohort will receive dostarlimab every 6 weeks). |
| Participants receiving dostarlimab plus belrestotug (Arm E) | EXPERIMENTAL | Participants will be administered IV infusions of dostarlimab followed by belrestotug, every 3 weeks. |
| Participants receiving dostarlimab plus belrestotug plus GSK6097608 (Arm F) | EXPERIMENTAL | Participants will be administered an IV infusion of dostarlimab followed by belrestotug followed by GSK6097608 every 3 weeks. |
| Participants receiving dostarlimab plus cobolimab (Arm G) | EXPERIMENTAL | Participants will be administered an IV infusion of cobolimab followed by dostarlimab |
| Name | Type | Description |
|---|---|---|
| GSK6097608 | DRUG | GSK6097608 will be administered as an IV infusion. |
| Dostarlimab | DRUG | Dostarlimab will be administered as an IV infusion. |
| Cobolimab | DRUG | Cobolimab will be administered as an IV infusion. |
| Belrestotug | DRUG | Belrestotug will be administered as an IV infusion. |
Inclusion Criteria: * Adults 18 years of age or older (or \>=20 years of age in Arm-A Japan, Arm-D Japan, Arm E-Japan, Arm F-Japan, and Arm G-Japan) * Female participants of childbearing potential must agree to use a highly effective form of contraception * Histological or cytological documentation...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
GSK6097608 is an investigational small molecule being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is currently in Phase 1 clinical development for advanced solid tumors.
GSK6097608 is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. The drug is in early-stage clinical development for oncology indications.
GSK6097608 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied for safety and effectiveness in patients with advanced solid tumors.
GSK6097608 is being studied in a Phase 1 clinical trial with the identifier NCT04446351. This trial is titled "Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors" and is active but not recruiting participants.
GSK6097608 is the code name for this investigational drug. No alternative brand names or other designations have been disclosed for this compound in its clinical development.